Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Cresco Labs Inc. sell kostojunior

Start price
€1.01
23.12.25 / 0%
Target price
€3.00
20.12.26
Performance (%)
2.77%
Price
€1.04
23.12.25
Summary
This prediction is currently active. The SELL prediction by kostojunior shows the price for Cresco Labs Inc. has slightly increased by 2.77%. This prediction currently runs until 20.12.26. The prediction end date can be changed by kostojunior at any time. This prediction was marked as speculative and is excluded from kostojunior's performance statistics.
Performance without dividends (%)
Name 1w
Cresco Labs Inc. 2.77%
iShares Core DAX® 0.650%
iShares Nasdaq 100 1.650%
iShares Nikkei 225® 1.232%
iShares S&P 500 1.413%

According to kostojunior what are the pros and cons of Cresco Labs Inc. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Normal challenges to pay loans and raise capital
Medium risks for its business
Revenue growth >5% per year expected
Future proof or reliable business model
Standard Investments for future growth
positive Cash Flow expected
Fair valuation
Cons

Comments by kostojunior for this prediction

In the thread Cresco Labs Inc. diskutieren
Prediction Sell
Perf. (%) 2.77%
Target price 3.000
Change
Ends at 20.12.26

Sell mit Kursziel 3,0

Stopped prediction by kostojunior for Cresco Labs Inc.

buy
Cresco Labs Inc.

Start price
Target price
Perf. (%)
€1.10
20.12.25
€3.00
20.12.26
-7.76%
23.12.25

Could be worthwhile Investment >10% per year
Normal challenges to pay loans and raise capital
Medium risks for its business
Revenue growth >5% per year expected
buy
Cresco Labs Inc.

Start price
Target price
Perf. (%)
€1.70
30.05.23
€2.00
30.05.24
-10.35%
10.06.23

Could be worthwhile Investment >10% per year
Normal challenges to pay loans and raise capital
Medium risks for its business
Revenue growth >5% per year expected